JP2005509403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005509403A5 JP2005509403A5 JP2002575087A JP2002575087A JP2005509403A5 JP 2005509403 A5 JP2005509403 A5 JP 2005509403A5 JP 2002575087 A JP2002575087 A JP 2002575087A JP 2002575087 A JP2002575087 A JP 2002575087A JP 2005509403 A5 JP2005509403 A5 JP 2005509403A5
- Authority
- JP
- Japan
- Prior art keywords
- culture
- nghc
- osmolality
- antibody
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 238000004113 cell culture Methods 0.000 claims description 17
- 102000004965 antibodies Human genes 0.000 claims description 14
- 108090001123 antibodies Proteins 0.000 claims description 14
- 241000699802 Cricetulus griseus Species 0.000 claims description 8
- 210000001672 Ovary Anatomy 0.000 claims description 7
- 102000005614 monoclonal antibodies Human genes 0.000 claims description 6
- 108010045030 monoclonal antibodies Proteins 0.000 claims description 6
- 230000000295 complement Effects 0.000 claims description 3
- 230000001472 cytotoxic Effects 0.000 claims description 2
- 230000001419 dependent Effects 0.000 claims description 2
- 239000002609 media Substances 0.000 description 72
- 210000004027 cells Anatomy 0.000 description 25
- 102000004851 Immunoglobulin G Human genes 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000005755 formation reaction Methods 0.000 description 15
- 230000003899 glycosylation Effects 0.000 description 12
- 238000006206 glycosylation reaction Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 9
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 102100016020 IFNG Human genes 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 101700086956 IFNG Proteins 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 150000002482 oligosaccharides Polymers 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000003247 decreasing Effects 0.000 description 5
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 4
- 229960000060 monoclonal antibodies Drugs 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 229940098773 Bovine Serum Albumin Drugs 0.000 description 3
- 108091003117 Bovine Serum Albumin Proteins 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 102000007312 Recombinant Proteins Human genes 0.000 description 3
- 108010033725 Recombinant Proteins Proteins 0.000 description 3
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 3
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000001720 carbohydrates Chemical group 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000001963 growth media Substances 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229960000187 tissue plasminogen activator Drugs 0.000 description 3
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 210000004408 Hybridomas Anatomy 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001105 regulatory Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UOMQUZPKALKDCA-UHFFFAOYSA-K 2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate;iron(3+) Chemical compound [Fe+3].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UOMQUZPKALKDCA-UHFFFAOYSA-K 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 102100015671 CSH2 Human genes 0.000 description 1
- 210000001736 Capillaries Anatomy 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229960002442 Glucosamine Drugs 0.000 description 1
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N Ranolazine Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229940029983 VITAMINS Drugs 0.000 description 1
- 229940021016 Vitamin IV solution additives Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 230000037348 biosynthesis Effects 0.000 description 1
- 239000006143 cell culture media Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108091006028 chimera Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000033581 fucosylation Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000004301 light adaptation Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 229960000213 ranolazine Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
Images
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27902601P | 2001-03-27 | 2001-03-27 | |
| PCT/US2002/009998 WO2002076578A1 (fr) | 2001-03-27 | 2002-03-27 | Mat de fibres metalliques a utiliser dans des filtres et procede de fabrication de ces filtres |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005509403A JP2005509403A (ja) | 2005-04-14 |
| JP2005509403A5 true JP2005509403A5 (fr) | 2008-06-26 |
Family
ID=23067363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002575087A Pending JP2005509403A (ja) | 2001-03-27 | 2002-03-27 | ＩｇＧにおけるグリコフォームの制御 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1373547A4 (fr) |
| JP (1) | JP2005509403A (fr) |
| AU (1) | AU2002256005A1 (fr) |
| WO (1) | WO2002076578A1 (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2137655T3 (pl) * | 2007-04-16 | 2012-12-31 | Momenta Pharmaceuticals Inc | Zdefiniowane produkty glikoproteinowe i powiązane sposoby |
| DK3216802T3 (da) | 2007-08-20 | 2021-01-04 | Glaxo Group Ltd | Produktionsfremgangsmåde |
| PL2493922T3 (pl) | 2009-10-26 | 2017-07-31 | F.Hoffmann-La Roche Ag | Sposób wytwarzania glikozylowanych immunoglobulin |
| BR112012025645A2 (pt) | 2010-04-07 | 2017-12-12 | Momenta Pharmaceuticals Inc | glicanos de alta manose. |
| CA2795461C (fr) | 2010-04-26 | 2018-04-24 | Novartis Ag | Procede ameliore de culture cellulaire |
| WO2012125553A2 (fr) | 2011-03-12 | 2012-09-20 | Momenta Pharmaceuticals, Inc. | N-glycanes contenant de la n-acétylhexosamine dans des produits de glycoprotéines |
| CA2829774C (fr) | 2011-03-14 | 2019-09-24 | National Research Council Of Canada | Procede de production virale dans des cellules |
| EP2702077A2 (fr) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013181575A2 (fr) | 2012-06-01 | 2013-12-05 | Momenta Pharmaceuticals, Inc. | Méthodes associées au denosumab |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| EP2855533A4 (fr) | 2013-03-15 | 2015-11-25 | Momenta Pharmaceuticals Inc | Procédés se rapportant à des protéines de fusion fc-ctla4 |
| ES2708759T3 (es) | 2013-05-13 | 2019-04-11 | Momenta Pharmaceuticals Inc | Procedimientos para el tratamiento de la neurodegeneración |
| BR112015032960B1 (pt) | 2013-07-04 | 2021-01-05 | F. Hoffmann-La Roche Ag | imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro |
| CN105431454A (zh) * | 2013-07-06 | 2016-03-23 | 卡迪拉保健有限公司 | 用于生产单克隆抗体的改进方法 |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| EP3058084A4 (fr) | 2013-10-16 | 2017-07-05 | Momenta Pharmaceuticals, Inc. | Glycoprotéines sialylées |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| CA2943667C (fr) * | 2014-01-29 | 2022-11-08 | Lg Life Sciences Ltd. | Methode servant a moduler la galactosylation de proteine recombinante au moyen de l'optimisation d'un substrat de culture |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1304918A (en) * | 1919-05-27 | Exlter medium ob other abticiie of mauufactitbe | ||
| US1898027A (en) * | 1929-01-10 | 1933-02-21 | Charles A Winslow | Air filter |
| US2271662A (en) * | 1939-01-17 | 1942-02-03 | Rubissow George Alexis | Filtering element and new method for its manufacture |
| US2217370A (en) * | 1939-08-08 | 1940-10-08 | Socony Vacuum Oil Co Inc | Screen wrapped perforated liner pipe |
| US3383278A (en) * | 1967-09-27 | 1968-05-14 | Appleton Mills | Adjustable woven fabric |
| US3502116A (en) * | 1967-11-29 | 1970-03-24 | Nat Standard Co | Woven filter cloth |
| US4048075A (en) * | 1974-05-06 | 1977-09-13 | The Carborundum Company | Filter cartridge |
| US5256291A (en) * | 1992-04-16 | 1993-10-26 | Cagle William S | Screen for filtering undesirable particles from a liquid |
| US5673483A (en) * | 1994-05-25 | 1997-10-07 | Morton International, Inc. | Method for constructing an inflator filter made of wrapped mesh |
| US5711879A (en) * | 1996-03-04 | 1998-01-27 | American Metal Fibers | Radial-flow filter and method of manufacture |
| DE59813187D1 (de) * | 1997-12-03 | 2005-12-15 | Roche Diagnostics Gmbh | Verfahren zur herstellung von polypeptiden mit geeigneter glykosilierung |
| WO2000045937A1 (fr) * | 1999-02-02 | 2000-08-10 | N.V. Bekaert S.A. | Cartouche filtrante à enroulement de faisceaux de fibres |
| ATE348173T1 (de) * | 1999-04-26 | 2007-01-15 | Genentech Inc | Zellenzuchtverfahren für glycoproteine |
-
2002
- 2002-03-27 AU AU2002256005A patent/AU2002256005A1/en not_active Abandoned
- 2002-03-27 WO PCT/US2002/009998 patent/WO2002076578A1/fr active Application Filing
- 2002-03-27 EP EP02725443A patent/EP1373547A4/fr not_active Ceased
- 2002-03-27 JP JP2002575087A patent/JP2005509403A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005509403A5 (fr) | ||
| JP2005509403A (ja) | ＩｇＧにおけるグリコフォームの制御 | |
| US20040214289A1 (en) | Control of glycoforms in IgG | |
| KR101560421B1 (ko) | 세포 배양물에서의 낮은 온도 및/또는 낮은 ｐＨ의 사용 | |
| DE69635076T2 (de) | Verfahren zur kontrollierung der sialylierung von durch säugetierzellkultur hergestelltem protein | |
| AU2017255538B2 (en) | Cell culture medium | |
| AU2014288811B2 (en) | Improved process for production of monoclonal antibodies | |
| EP2904092B1 (fr) | Compositions et procédés de production de glycoprotéines | |
| CN114990049B (zh) | 一种同时调节细胞表达产物的糖型和电荷异质性的方法 | |
| AU2016354052B2 (en) | Methods for modulating production profiles of recombinant proteins | |
| EP3728621A2 (fr) | Procédés de modulation de profils de mannosylation de protéines à l'aide d'un ionophore de polyéther | |
| CA3031512C (fr) | Procede de reduction des produits derives non souhaitables dans la culture de cellules dis ip | |
| EP3455363B1 (fr) | Procédés de modulation des profils de galactosylation de protéines recombinantes au moyen de galactose de peracétyle | |
| CN111373028B (zh) | 蛋白质的生产方法 | |
| TR2022003651T2 (tr) | Anti̇kor üreti̇mi̇nde fukozi̇lasyon ve temel varyantlari azaltmaya yöneli̇k hücre kültürü ortami | |
| WO2021066772A1 (fr) | Milieu de culture cellulaire pour réduire la fucosylation et des variants basiques dans la production d'anticorps | |
| Faife et al. | Effects of selection and adaptation of NS0 cells to protein-free medium on the properties, affinity and biological activity of a monoclonal antibody | |
| WO2016162514A1 (fr) | Procédés de modulation des profils de glycosylation des protéines de protéines de recombinaison |